{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T15:34:41Z","timestamp":1794929681022,"version":"4.9.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["D171100000517003"],"award-info":[{"award-number":["D171100000517003"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["D171100000517001"],"award-info":[{"award-number":["D171100000517001"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Epstein-Barr virus (EBV) is associated with a range of epithelial and B cell malignancies as well as autoimmune disorders, for which there are still no specific treatments or effective vaccines. Here, we isolate EBV gH\/gL-specific antibodies from an EBV-infected individual. One antibody, 1D8, efficiently neutralizes EBV infection of two major target cell types, B cells and epithelial cells. In humanized mice, 1D8 provides protection against a high-dose EBV challenge by substantially reducing viral loads and associated tumor burden. Crystal structure analysis reveals that 1D8 binds to a key vulnerable interface between the D-I\/D-II domains of the viral gH\/gL protein, especially the D-II of the gH, thereby interfering with the gH\/gL-mediated membrane fusion and binding to target cells. Overall, we identify a potent and protective neutralizing antibody capable of reducing the EBV load. The novel vulnerable site represents an attractive target that is potentially important for antibody and vaccine intervention against EBV infection.<\/jats:p>","DOI":"10.1038\/s41467-021-26912-6","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T06:07:24Z","timestamp":1637042844000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus"],"prefix":"10.1038","volume":"12","author":[{"given":"Qian-Ying","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7184-6818","authenticated-orcid":false,"given":"Sisi","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2294-0752","authenticated-orcid":false,"given":"Jinfang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Ying","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1786-7420","authenticated-orcid":false,"given":"Cong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Yi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Mei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Jian","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Mei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3136-8070","authenticated-orcid":false,"given":"Xinquan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3509-5591","authenticated-orcid":false,"given":"Mu-Sheng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4931-509X","authenticated-orcid":false,"given":"Linqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"key":"26912_CR1","unstructured":"de-Th\u00e9 G., et al. Sero-epidemiology of the Epstein-Barr virus: preliminary analysis of an international study\u2014a review. IARC Sci Publ, 3-16 (1975)."},{"key":"26912_CR2","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc.2016.92","volume":"16","author":"LS Young","year":"2016","unstructured":"Young, L. S., Yap, L. F. & Murray, P. G. Epstein-Barr virus: more than 50 years old and still providing surprises. Nat. Rev. Cancer 16, 789\u2013802 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"26912_CR3","doi-asserted-by":"publisher","first-page":"107fs107","DOI":"10.1126\/scitranslmed.3002878","volume":"3","author":"JI Cohen","year":"2011","unstructured":"Cohen, J. I., Fauci, A. S., Varmus, H. & Nabel, G. J. Epstein-Barr virus: an important vaccine target for cancer prevention. Sci. Transl. Med. 3, 107fs107 (2011).","journal-title":"Sci. Transl. Med."},{"key":"26912_CR4","doi-asserted-by":"crossref","first-page":"581","DOI":"10.5732\/cjc.014.10208","volume":"33","author":"LS Young","year":"2014","unstructured":"Young, L. S. & Dawson, C. W. Epstein-Barr virus and nasopharyngeal carcinoma. Chin. J. Cancer 33, 581\u2013590 (2014).","journal-title":"Chin. J. Cancer"},{"key":"26912_CR5","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/cac2.12100","volume":"40","author":"R Tan","year":"2020","unstructured":"Tan, R. et al. Clinical utility of Epstein-Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma. Cancer Commun. (Lond.) 40, 564\u2013585 (2020).","journal-title":"Cancer Commun. (Lond.)"},{"key":"26912_CR6","doi-asserted-by":"crossref","unstructured":"Henrickson, S. E. To EBV or not to EBV: Rational vaccine design for a common infection. Sci Immunol 3, eaat9661 (2018).","DOI":"10.1126\/sciimmunol.aat9661"},{"key":"26912_CR7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3389\/fonc.2019.00104","volume":"9","author":"DG van Zyl","year":"2019","unstructured":"van Zyl, D. G., Mautner, J. & Delecluse, H. J. Progress in EBV vaccines. Front Oncol. 9, 104 (2019).","journal-title":"Front Oncol."},{"key":"26912_CR8","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1038\/cti.2014.27","volume":"4","author":"JI Cohen","year":"2015","unstructured":"Cohen, J. I. Epstein-barr virus vaccines. Clin. Transl. Immunol. 4, e32 (2015).","journal-title":"Clin. Transl. Immunol."},{"key":"26912_CR9","doi-asserted-by":"publisher","first-page":"B194","DOI":"10.1016\/j.vaccine.2012.09.041","volume":"31","author":"JI Cohen","year":"2013","unstructured":"Cohen, J. I., Mocarski, E. S., Raab-Traub, N., Corey, L. & Nabel, G. J. The need and challenges for development of an Epstein-Barr virus vaccine. Vaccine 31, B194\u2013B196 (2013).","journal-title":"Vaccine"},{"key":"26912_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/cac2.12006","volume":"40","author":"LS Young","year":"2020","unstructured":"Young, L. S. A novel Epstein-Barr virus subtype associated with nasopharyngeal carcinoma found in South China. Cancer Commun. (Lond.) 40, 60\u201362 (2020).","journal-title":"Cancer Commun. (Lond.)"},{"key":"26912_CR11","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.immuni.2019.03.010","volume":"50","author":"W Bu","year":"2019","unstructured":"Bu, W. et al. Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein-Barr virus in B cells and epithelial cells. Immunity 50, 1305\u20131316 e1306 (2019).","journal-title":"Immunity"},{"key":"26912_CR12","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1158\/1078-0432.CCR-15-2299","volume":"22","author":"AE Coghill","year":"2016","unstructured":"Coghill, A. E. et al. High levels of antibody that neutralize B-cell infection of Epstein-Barr virus and that bind EBV gp350 are associated with a lower risk of nasopharyngeal carcinoma. Clin. Cancer Res 22, 3451\u20133457 (2016).","journal-title":"Clin. Cancer Res"},{"key":"26912_CR13","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/infdis\/jiy250","volume":"218","author":"AE Coghill","year":"2018","unstructured":"Coghill, A. E. et al. Evaluation of total and IgA-specific antibody targeting Epstein-Barr virus glycoprotein 350 and nasopharyngeal carcinoma risk. J. Infect. Dis. 218, 886\u2013891 (2018).","journal-title":"J. Infect. Dis."},{"key":"26912_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1128\/CVI.00674-15","volume":"23","author":"W Bu","year":"2016","unstructured":"Bu, W. et al. Kinetics of Epstein-Barr virus (EBV) neutralizing and virus-specific antibodies after primary infection with EBV. Clin. Vaccin. Immunol. 23, 363\u2013369 (2016).","journal-title":"Clin. Vaccin. Immunol."},{"key":"26912_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.virol.2009.06.013","volume":"391","author":"J Sashihara","year":"2009","unstructured":"Sashihara, J., Burbelo, P. D., Savoldo, B., Pierson, T. C. & Cohen, J. I. Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay. Virology 391, 249\u2013256 (2009).","journal-title":"Virology"},{"key":"26912_CR16","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","volume":"19","author":"D Sok","year":"2018","unstructured":"Sok, D. & Burton, D. R. Recent progress in broadly neutralizing antibodies to HIV. Nat. Immunol. 19, 1179\u20131188 (2018).","journal-title":"Nat. Immunol."},{"key":"26912_CR17","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/s41590-018-0233-9","volume":"19","author":"EO Saphire","year":"2018","unstructured":"Saphire, E. O., Schendel, S. L., Gunn, B. M., Milligan, J. C. & Alter, G. Antibody-mediated protection against Ebola virus. Nat. Immunol. 19, 1169\u20131178 (2018).","journal-title":"Nat. Immunol."},{"key":"26912_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41392-020-00318-0","volume":"5","author":"F Yu","year":"2020","unstructured":"Yu, F. et al. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Signal Transduct. Target Ther. 5, 212 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"26912_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nri.2017.148","volume":"18","author":"LM Walker","year":"2018","unstructured":"Walker, L. M. & Burton, D. R. Passive immunotherapy of viral infections: \u2018super-antibodies\u2019 enter the fray. Nat. Rev. Immunol. 18, 297\u2013308 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"26912_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.coi.2016.06.001","volume":"41","author":"A Lanzavecchia","year":"2016","unstructured":"Lanzavecchia, A., Fruhwirth, A., Perez, L. & Corti, D. Antibody-guided vaccine design: identification of protective epitopes. Curr. Opin. Immunol. 41, 62\u201367 (2016).","journal-title":"Curr. Opin. Immunol."},{"key":"26912_CR21","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2217\/fvl.15.80","volume":"10","author":"LM Hutt-Fletcher","year":"2015","unstructured":"Hutt-Fletcher, L. M. EBV glycoproteins: where are we now? Future Virol. 10, 1155\u20131162 (2015).","journal-title":"Future Virol."},{"key":"26912_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/bs.aivir.2019.05.006","volume":"104","author":"BS Mohl","year":"2019","unstructured":"Mohl, B. S., Chen, J. & Longnecker, R. Gammaherpesvirus entry and fusion: a tale how two human pathogenic viruses enter their host cells. Adv. Virus Res 104, 313\u2013343 (2019).","journal-title":"Adv. Virus Res"},{"key":"26912_CR23","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1086\/505912","volume":"194","author":"T Haque","year":"2006","unstructured":"Haque, T. et al. A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivo. J. Infect. Dis. 194, 584\u2013587 (2006).","journal-title":"J. Infect. Dis."},{"key":"26912_CR24","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.immuni.2018.03.026","volume":"48","author":"J Snijder","year":"2018","unstructured":"Snijder, J. et al. An antibody targeting the fusion machinery neutralizes dual-tropic infection and defines a site of vulnerability on Epstein-Barr virus. Immunity 48, 799\u2013811 e799 (2018).","journal-title":"Immunity"},{"key":"26912_CR25","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1016\/j.vaccine.2016.06.021","volume":"34","author":"X Cui","year":"2016","unstructured":"Cui, X. et al. Rabbits immunized with Epstein-Barr virus gH\/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350. Vaccine 34, 4050\u20134055 (2016).","journal-title":"Vaccine"},{"key":"26912_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/mco2.32","volume":"2","author":"Q-Y Zhu","year":"2021","unstructured":"Zhu, Q.-Y. et al. Advances in pathogenesis and precision medicine for nasopharyngeal carcinoma. MedComm. 2, 175\u2013206 (2021).","journal-title":"MedComm."},{"key":"26912_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nrmicro2548","volume":"9","author":"SA Connolly","year":"2011","unstructured":"Connolly, S. A., Jackson, J. O., Jardetzky, T. S. & Longnecker, R. Fusing structure and function: a structural view of the herpesvirus entry machinery. Nat. Rev. Microbiol. 9, 369\u2013381 (2011).","journal-title":"Nat. Rev. Microbiol."},{"key":"26912_CR28","doi-asserted-by":"crossref","unstructured":"Singh, S., et al. Neutralizing antibodies protect against oral transmission of lymphocryptovirus. Cell Rep. Med. 1, 100033(2020).","DOI":"10.1016\/j.xcrm.2020.100033"},{"key":"26912_CR29","doi-asserted-by":"publisher","first-page":"286","DOI":"10.14348\/molcells.2016.0066","volume":"39","author":"BS Mohl","year":"2016","unstructured":"Mohl, B. S., Chen, J., Sathiyamoorthy, K., Jardetzky, T. S. & Longnecker, R. Structural and Mechanistic Insights into the Tropism of Epstein-Barr Virus. Mol. Cells 39, 286\u2013291 (2016).","journal-title":"Mol. Cells"},{"key":"26912_CR30","doi-asserted-by":"crossref","unstructured":"Connolly, S. A., Jardetzky, T. S. & Longnecker, R. The structural basis of herpesvirus entry. Nat. Rev. Microbiol. 19, 110\u2013121 (2020).","DOI":"10.1038\/s41579-020-00448-w"},{"key":"26912_CR31","first-page":"545","volume":"33","author":"LS Chesnokova","year":"2014","unstructured":"Chesnokova, L. S. & Hutt-Fletcher, L. M. Epstein-Barr virus infection mechanisms. Chin. J. Cancer 33, 545\u2013548 (2014).","journal-title":"Chin. J. Cancer"},{"key":"26912_CR32","doi-asserted-by":"publisher","first-page":"22641","DOI":"10.1073\/pnas.1011806108","volume":"107","author":"H Matsuura","year":"2010","unstructured":"Matsuura, H., Kirschner, A. N., Longnecker, R. & Jardetzky, T. S. Crystal structure of the Epstein-Barr virus (EBV) glycoprotein H\/glycoprotein L (gH\/gL) complex. Proc. Natl Acad. Sci. USA 107, 22641\u201322646 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"26912_CR33","doi-asserted-by":"publisher","first-page":"13570","DOI":"10.1128\/JVI.02272-14","volume":"88","author":"BS Mohl","year":"2014","unstructured":"Mohl, B. S., Sathiyamoorthy, K., Jardetzky, T. S. & Longnecker, R. The conserved disulfide bond within domain II of Epstein-Barr virus gH has divergent roles in membrane fusion with epithelial cells and B cells. J. Virol. 88, 13570\u201313579 (2014).","journal-title":"J. Virol."},{"key":"26912_CR34","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1128\/JVI.03245-12","volume":"87","author":"J Chen","year":"2013","unstructured":"Chen, J., Jardetzky, T. S. & Longnecker, R. The large groove found in the gH\/gL structure is an important functional domain for Epstein-Barr virus fusion. J. Virol. 87, 3620\u20133627 (2013).","journal-title":"J. Virol."},{"key":"26912_CR35","doi-asserted-by":"publisher","first-page":"e1004309","DOI":"10.1371\/journal.ppat.1004309","volume":"10","author":"K Sathiyamoorthy","year":"2014","unstructured":"Sathiyamoorthy, K. et al. Assembly and architecture of the EBV B cell entry triggering complex. PLoS Pathog. 10, e1004309 (2014).","journal-title":"PLoS Pathog."},{"key":"26912_CR36","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","volume":"162","author":"M Kanekiyo","year":"2015","unstructured":"Kanekiyo, M. et al. Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site. Cell 162, 1090\u20131100 (2015).","journal-title":"Cell"},{"key":"26912_CR37","doi-asserted-by":"publisher","first-page":"11217","DOI":"10.1128\/JVI.01673-08","volume":"82","author":"KA Young","year":"2008","unstructured":"Young, K. A., Herbert, A. P., Barlow, P. N., Holers, V. M. & Hannan, J. P. Molecular basis of the interaction between complement receptor type 2 (CR2\/CD21) and Epstein-Barr virus glycoprotein gp350. J. Virol. 82, 11217\u201311227 (2008).","journal-title":"J. Virol."},{"key":"26912_CR38","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/nsmb1161","volume":"13","author":"G Szakonyi","year":"2006","unstructured":"Szakonyi, G. et al. Structure of the Epstein-Barr virus major envelope glycoprotein. Nat. Struct. Mol. Biol. 13, 996\u20131001 (2006).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"26912_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13557","volume":"7","author":"K Sathiyamoorthy","year":"2016","unstructured":"Sathiyamoorthy, K. et al. Structural basis for Epstein-Barr virus host cell tropism mediated by gp42 and gHgL entry glycoproteins. Nat. Commun. 7, 13557 (2016).","journal-title":"Nat. Commun."},{"key":"26912_CR40","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1097-2765(02)00465-3","volume":"9","author":"MM Mullen","year":"2002","unstructured":"Mullen, M. M., Haan, K. M., Longnecker, R. & Jardetzky, T. S. Structure of the Epstein-Barr virus gp42 protein bound to the MHC class II receptor HLA-DR1. Mol. Cell 9, 375\u2013385 (2002).","journal-title":"Mol. Cell"},{"key":"26912_CR41","doi-asserted-by":"publisher","first-page":"9444","DOI":"10.1128\/JVI.00572-06","volume":"80","author":"AN Kirschner","year":"2006","unstructured":"Kirschner, A. N., Omerovic, J., Popov, B., Longnecker, R. & Jardetzky, T. S. Soluble Epstein-Barr virus glycoproteins gH, gL, and gp42 form a 1:1:1 stable complex that acts like soluble gp42 in B-cell fusion but not in epithelial cell fusion. J. Virol. 80, 9444\u20139454 (2006).","journal-title":"J. Virol."},{"key":"26912_CR42","doi-asserted-by":"publisher","first-page":"11036","DOI":"10.1073\/pnas.1513359112","volume":"112","author":"D Xiong","year":"2015","unstructured":"Xiong, D. et al. Nonmuscle myosin heavy chain IIA mediates Epstein-Barr virus infection of nasopharyngeal epithelial cells. Proc. Natl Acad. Sci. USA 112, 11036\u201311041 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"26912_CR43","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41564-017-0081-7","volume":"3","author":"J Chen","year":"2018","unstructured":"Chen, J. et al. Ephrin receptor A2 is a functional entry receptor for Epstein-Barr virus. Nat. Microbiol. 3, 172\u2013180 (2018).","journal-title":"Nat. Microbiol."},{"key":"26912_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41564-017-0080-8","volume":"3","author":"H Zhang","year":"2018","unstructured":"Zhang, H. et al. Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry. Nat. Microbiol. 3, 1\u20138 (2018).","journal-title":"Nat. Microbiol."},{"key":"26912_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7240","volume":"6","author":"HB Wang","year":"2015","unstructured":"Wang, H. B. et al. Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells. Nat. Commun. 6, 6240 (2015).","journal-title":"Nat. Commun."},{"key":"26912_CR46","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/femsre\/fuz023","volume":"43","author":"J Chen","year":"2019","unstructured":"Chen, J. & Longnecker, R. Epithelial cell infection by Epstein-Barr virus. FEMS Microbiol. Rev. 43, 674\u2013683 (2019).","journal-title":"FEMS Microbiol. Rev."},{"key":"26912_CR47","doi-asserted-by":"publisher","first-page":"E8703","DOI":"10.1073\/pnas.1704661114","volume":"114","author":"K Sathiyamoorthy","year":"2017","unstructured":"Sathiyamoorthy, K. et al. Inhibition of EBV-mediated membrane fusion by anti-gHgL antibodies. Proc. Natl Acad. Sci. USA 114, E8703\u2013E8710 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"26912_CR48","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/aje\/kws404","volume":"177","author":"Z Liu","year":"2013","unstructured":"Liu, Z. et al. Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening: results from the initial phase of a cluster randomized controlled trial in Southern China. Am. J. Epidemiol. 177, 242\u2013250 (2013).","journal-title":"Am. J. Epidemiol."},{"key":"26912_CR49","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/ijc.26380","volume":"131","author":"Y Liu","year":"2012","unstructured":"Liu, Y. et al. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China. Int J. Cancer 131, 406\u2013416 (2012).","journal-title":"Int J. Cancer"},{"key":"26912_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2014.88","volume":"47","author":"S Fujiwara","year":"2015","unstructured":"Fujiwara, S., Imadome, K. & Takei, M. Modeling EBV infection and pathogenesis in new-generation humanized mice. Exp. Mol. Med. 47, e135 (2015).","journal-title":"Exp. Mol. Med."},{"key":"26912_CR51","doi-asserted-by":"publisher","first-page":"13081","DOI":"10.1073\/pnas.1407075112","volume":"112","author":"EK Lee","year":"2015","unstructured":"Lee, E. K. et al. Effects of lymphocyte profile on development of EBV-induced lymphoma subtypes in humanized mice. Proc. Natl Acad. Sci. USA 112, 13081\u201313086 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"26912_CR52","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.coviro.2017.07.026","volume":"25","author":"C Munz","year":"2017","unstructured":"Munz, C. Humanized mouse models for Epstein Barr virus infection. Curr. Opin. Virol. 25, 113\u2013118 (2017).","journal-title":"Curr. Opin. Virol."},{"key":"26912_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/srep06881","volume":"4","author":"J Audet","year":"2014","unstructured":"Audet, J. et al. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus. Sci. Rep. 4, 6881 (2014).","journal-title":"Sci. Rep."},{"key":"26912_CR54","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1086\/590502","volume":"198","author":"M Yajima","year":"2008","unstructured":"Yajima, M. et al. A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J. Infect. Dis. 198, 673\u2013682 (2008).","journal-title":"J. Infect. Dis."},{"key":"26912_CR55","doi-asserted-by":"crossref","unstructured":"Caves, E. A. et al. Air-liquid interface method to study Epstein-Barr virus pathogenesis in nasopharyngeal epithelial cells. mSphere 3, e00152 (2018).","DOI":"10.1128\/mSphere.00152-18"},{"key":"26912_CR56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jviromet.2017.04.012","volume":"247","author":"R Lin","year":"2017","unstructured":"Lin, R. et al. Development of a robust, higher throughput green fluorescent protein (GFP)-based Epstein-Barr Virus (EBV) micro-neutralization assay. J. Virol. Methods 247, 15\u201321 (2017).","journal-title":"J. Virol. Methods"},{"key":"26912_CR57","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1128\/CMR.00044-10","volume":"24","author":"OA Odumade","year":"2011","unstructured":"Odumade, O. A., Hogquist, K. A. & Balfour, H. H. Jr. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin. Microbiol Rev. 24, 193\u2013209 (2011).","journal-title":"Clin. Microbiol Rev."},{"key":"26912_CR58","doi-asserted-by":"publisher","first-page":"12408","DOI":"10.1128\/JVI.79.19.12408-12415.2005","volume":"79","author":"J Omerovic","year":"2005","unstructured":"Omerovic, J., Lev, L. & Longnecker, R. The amino terminus of Epstein-Barr virus glycoprotein gH is important for fusion with epithelial and B cells. J. Virol. 79, 12408\u201312415 (2005).","journal-title":"J. Virol."},{"key":"26912_CR59","doi-asserted-by":"crossref","unstructured":"Mohl, B. S., Chen, J., Park, S. J., Jardetzky, T. S. & Longnecker, R. Epstein-Barr virus fusion with epithelial cells triggered by gB is restricted by a gL glycosylation site. J. Virol. 91, e01255 (2017).","DOI":"10.1128\/JVI.01255-17"},{"key":"26912_CR60","doi-asserted-by":"crossref","unstructured":"Zhu, Q. Y. et al. Association between antibody responses to Epstein-Barr virus glycoproteins, neutralization of infectivity, and the risk of nasopharyngeal carcinoma. mSphere 5, e00901 (2020).","DOI":"10.1128\/mSphere.00901-20"},{"key":"26912_CR61","first-page":"341","volume":"15","author":"F Zhan","year":"1998","unstructured":"Zhan, F. et al. [Primary study of differentially expressed cDNA sequences in cell line HNE1 of human nasopharyngeal carcinoma by cDNA representational difference analysis]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 15, 341\u2013344 (1998).","journal-title":"Zhonghua Yi Xue Yi Chuan Xue Za Zhi"},{"key":"26912_CR62","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/ijc.2910260202","volume":"26","author":"DP Huang","year":"1980","unstructured":"Huang, D. P. et al. Establishment of a cell line (NPC\/HK1) from a differentiated squamous carcinoma of the nasopharynx. Int J. Cancer 26, 127\u2013132 (1980).","journal-title":"Int J. Cancer"},{"key":"26912_CR63","doi-asserted-by":"publisher","first-page":"6324","DOI":"10.1128\/JVI.74.14.6324-6332.2000","volume":"74","author":"SJ Molesworth","year":"2000","unstructured":"Molesworth, S. J., Lake, C. M., Borza, C. M., Turk, S. M. & Hutt-Fletcher, L. M. Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells. J. Virol. 74, 6324\u20136332 (2000).","journal-title":"J. Virol."},{"key":"26912_CR64","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1096\/fj.201800617R","volume":"33","author":"S Guo","year":"2019","unstructured":"Guo, S. et al. Oncological and genetic factors impacting PDX model construction with NSG mice in pancreatic cancer. FASEB J. 33, 873\u2013884 (2019).","journal-title":"FASEB J."},{"key":"26912_CR65","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jviromet.2009.02.014","volume":"158","author":"HX Liao","year":"2009","unstructured":"Liao, H. X. et al. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J. Virol. Methods 158, 171\u2013179 (2009).","journal-title":"J. Virol. Methods"},{"key":"26912_CR66","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nmeth.4193","volume":"14","author":"SQ Zheng","year":"2017","unstructured":"Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331\u2013332 (2017).","journal-title":"Nat. Methods"},{"key":"26912_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsb.2015.11.003","volume":"193","author":"K Zhang","year":"2016","unstructured":"Zhang, K. Gctf: Real-time CTF determination and correction. J. Struct. Biol. 193, 1\u201312 (2016).","journal-title":"J. Struct. Biol."},{"key":"26912_CR68","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1107\/S2052252520000081","volume":"7","author":"J Zivanov","year":"2020","unstructured":"Zivanov, J., Nakane, T. & Scheres, S. H. W. Estimation of high-order aberrations and anisotropic magnification from cryo-EM data sets in RELION-3.1. IUCrJ 7, 253\u2013267 (2020).","journal-title":"IUCrJ"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26912-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26912-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26912-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T14:11:15Z","timestamp":1675865475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26912-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["26912"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-26912-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-151895\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,16]]},"assertion":[{"value":"20 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: Patent applications have been filed on monoclonal antibodies that cover 1D8 presented here (patent application number: CN202010363336.X; patent applicants: Sun Yat-sen University Cancer Center and Tsinghua University). Q.Z., S.S., S.C., L.Z., and M.Z. are the inventors. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6624"}}